---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-036818"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:21:35.821930+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech subsidiary Cyprium closes PRV sale for $205M; Fortress expects over $100M

## Summary
- Cyprium sold Rare Pediatric Disease Priority Review Voucher for $205M gross proceeds.
- Fortress (80.4% owner) expects over $100M from dividends and intercompany agreements.
- PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on Jan 12, 2026.
- Cyprium redeemed all outstanding 9.375% Perpetual Preferred Stock in connection with sale.
- Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to ~$128M in milestones.

## SEC filing metadata
- accession: 0001104659-26-036818
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/0001104659-26-036818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/fbio-20260330x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-036818
- JSON: https://secwatch.observer/filing/0001104659-26-036818.json
- Plain text: https://secwatch.observer/filing/0001104659-26-036818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.